Axonics Modulation Technologies Inc

Market Summary

USD57.88+0.53

Market Closed

0.92%

AXNX Alerts

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)

AXNX Stock Price

View Fullscreen

AXNX RSI Chart

AXNX Alerts

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)

AXNX Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-244.83

Price/Sales (Trailing)

8.56

EV/EBITDA

-1.5K

Price/Free Cashflow

-3.4K

AXNX Price/Sales (Trailing)

AXNX Profitability

EBT Margin

-10.73%

Return on Equity

-5.36%

Return on Assets

-4.96%

Free Cashflow Yield

-0.03%

AXNX Fundamentals

AXNX Revenue

Revenue (TTM)

342.6M

Revenue Y/Y

32.27%

Revenue Q/Q

0.22%

AXNX Earnings

Earnings (TTM)

-12.0M

Earnings Y/Y

124.17%

Earnings Q/Q

153.5%

Price Action

Last 7 days

3.4%

Last 30 days

8.3%

Last 90 days

-0.4%

Trailing 12 Months

-12.2%

How does AXNX drawdown profile look like?

AXNX Financial Health

Current Ratio

14.19

AXNX Investor Care

Shares Dilution (1Y)

7.33%

Diluted EPS (TTM)

-0.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	295.9M	319.8M	342.6M	0
2022	194.3M	217.4M	240.9M	273.7M
2021	119.6M	150.3M	161.9M	180.3M
2020	39.0M	52.8M	86.7M	111.5M
2019	2.0M	3.3M	4.4M	13.8M
2018	327.5K	454.0K	580.5K	707.0K
2017	0	0	0	201.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for AXNX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 29, 2023	dearen danny l.	sold	-436,490	56.8717	-7,675	president & cfo
Sep 29, 2023	dearen danny l.	acquired	-	-	11,250	president & cfo
Aug 15, 2023	ford alfred j jr	sold	-920,671	62.3381	-14,769	chief commercial officer
Aug 08, 2023	carrel michael h	gifted	-	-	-500	-
Jul 28, 2023	ford alfred j jr	sold	-93,021	62.014	-1,500	chief commercial officer
Jun 26, 2023	mcnamara robert	acquired	-	-	3,000	-
Jun 26, 2023	lopez esteban	acquired	-	-	3,000	-
Jun 26, 2023	carrel michael h	acquired	-	-	3,000	-
Jun 26, 2023	snyderman nancy lynn md	acquired	-	-	3,000	-
Jun 26, 2023	kiernan jane e	acquired	-	-	3,000	-

Which funds bought or sold AXNX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Dec 06, 2023	CITIGROUP INC	reduced	-97.52	-877,239	24,862	-%
Nov 24, 2023	DEUTSCHE BANK AG\	reduced	-35.02	-1,949,170	5,076,500	-%
Nov 22, 2023	Graham Capital Management, L.P.	sold off	-100	-2,652,750	-	-%
Nov 21, 2023	Walleye Capital LLC	reduced	-89.52	-1,602,940	211,404	-%
Nov 21, 2023	COMERICA BANK	reduced	-93.67	35,505	35,505	-%
Nov 17, 2023	Diversified Trust Co	added	15.02	152,312	698,245	0.03%
Nov 15, 2023	Bullseye Asset Management LLC	unchanged	-	234,000	2,325,000	1.30%
Nov 15, 2023	Integrated Wealth Concepts LLC	added	4.34	40,057	290,085	-%
Nov 15, 2023	iA Global Asset Management Inc.	reduced	-9.27	17,000	1,922,000	0.03%
Nov 15, 2023	MORGAN STANLEY	reduced	-39.9	-5,925,200	11,934,200	-%

Latest Funds Activity

Are funds buying AXNX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AXNX

No. of Funds

Schedule 13G FIlings of Axonics Modulation Technologies Inc

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 10, 2023	vanguard group inc	10.28%	5,092,888	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.82%	4,863,283	SC 13G/A
Jan 31, 2023	blackrock inc.	7.3%	3,630,843	SC 13G/A
Jun 06, 2022	cooperatieve gilde healthcare iv u.a.	0%	0	SC 13G/A
Feb 14, 2022	credit suisse ag/	4.90%	2,273,198	SC 13G/A
Feb 09, 2022	vanguard group inc	6.27%	2,902,696	SC 13G
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 03, 2022	blackrock inc.	7.6%	3,525,549	SC 13G/A
Apr 08, 2021	alfred e. mann foundation for scientific research	4.0%	1,602,970	SC 13G/A

Recent SEC filings of Axonics Modulation Technologies Inc

View All Filings

Date Filed	Form Type	Document
Oct 31, 2023	10-Q	Quarterly Report
Oct 30, 2023	8-K	Current Report
Oct 06, 2023	3	Insider Trading
Oct 04, 2023	8-K	Current Report
Oct 03, 2023	4/A	Insider Trading
Oct 03, 2023	4	Insider Trading

Peers (Alternatives to Axonics Modulation Technologies Inc)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.1B	40.0B	9.79%	-0.70%	35.09	4.53	-11.26%	-34.57%
BDX	71.3B	19.4B	-8.82%	-4.53%	44.09	3.79	2.66%	-16.58%
BAX	18.5B	15.0B	6.81%	-29.70%	7.13	1.23	3.01%	209.09%
ALGN	16.6B	3.8B	9.66%	15.63%	45.73	4.36	-1.48%	-28.97%
MID-CAP
HSIC	9.3B	12.7B	13.63%	-12.11%	20.89	0.73	0.68%	-30.25%
BIO	9.0B	2.7B	2.35%	-23.26%	-56.61	3.32	-3.01%	97.36%
ATR	8.3B	3.4B	1.55%	18.98%	29.56	2.41	3.13%	18.17%
XRAY	6.9B	3.9B	14.40%	9.17%	-31.57	1.75	-2.62%	73.28%
AXNX	2.9B	342.6M	8.31%	-12.22%	-244.83	8.56	42.19%	84.14%
PDCO	2.5B	6.6B	-12.97%	-7.64%	12.41	0.38	2.61%	0.62%
SMALL-CAP
AHCO	1.1B	3.1B	3.77%	-63.31%	-2.53	0.35	7.95%	-550.16%
ANIK	329.0M	163.3M	7.10%	-27.48%	-13.39	2.01	7.14%	-56.09%
ANGO	282.7M	335.9M	6.52%	-42.04%	43.86	0.84	4.71%	116.39%
APYX	72.1M	50.3M	-18.43%	13.66%	-4.75	1.43	3.23%	20.81%
AEMD	5.2M	3.8M	8.25%	-44.93%	-0.45	1.37	17.30%	10.67%

Axonics Modulation Technologies Inc News

Latest updates

Yahoo Finance • 06 Nov 2023 • 08:00 am • 32 days ago

Revolutionizing Care: NeuroQure's Groundbreaking Path to Treating ...

Huron Daily Tribune • 30 Oct 2023 • 08:33 pm • 38 days ago

Axonics: Q3 Earnings Snapshot

StreetInsider.com • 19 Aug 2020 • 07:00 am • 3 years ago

Form N-PX RYDEX DYNAMIC FUNDS For: Jun 30

Yahoo Finance • 05 Aug 2020 • 07:00 am • 3 years ago

Were Hedge Funds Right About Buying Cactus, Inc. (WHD)?

Yahoo Finance • 17 Jun 2020 • 07:00 am • 3 years ago

Is Axonics Modulation Technologies, Inc. (AXNX) Going to Burn ...

Nasdaq • 16 Jan 2020 • 08:00 am • 3 years ago

Lyn Alden's Positioning For 2020: A Diversified Global Focus

Yahoo Finance • 02 Nov 2019 • 07:00 am • 4 years ago

Have Insiders Been Selling Axonics Modulation Technologies, Inc ...

Business Wire • 02 Nov 2018 • 07:00 am • 5 years ago

Axonics® Announces Closing of Initial Public Offering of Common ...

MarketWatch • 31 Oct 2018 • 07:00 am • 5 years ago

Axonics prices IPO at $15 a share

Financials for Axonics Modulation Technologies Inc

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	0.2%	93,100,000	92,894,000	70,650,000	85,918,000	70,384,000	68,980,000	48,420,000	53,135,000	46,913,000	45,869,000	34,373,000	34,783,000	35,243,000	15,213,000	26,296,000	9,950,500	1,300,000	1,488,000	1,077,000	494,000	201,000
Gross Profit	-1.5%	69,104,000	70,190,000	52,500,000	62,967,000	51,260,000	50,196,000	33,242,000	35,391,000	31,194,000	28,734,000	20,399,000	22,131,000	21,809,000	6,750,000	16,401,000	5,408,000	677,000	716,000	529,000	249,000	95,000
Operating Expenses	-15.2%	69,791,000	82,260,000	66,866,000	66,576,000	67,635,000	71,625,000	56,775,000	53,071,000	47,696,000	44,744,000	42,015,000	33,012,000	30,578,000	26,155,000	31,106,000	28,071,000	25,724,000	19,986,000	14,148,000	9,700,000	7,637,000
S&GA Expenses	7.4%	47,544,000	44,270,000	42,654,000	43,824,000	39,751,000	39,381,000	33,063,000	31,338,000	28,112,000	25,411,000	20,928,000	18,284,000	17,057,000	14,220,000	16,569,000	16,301,000	15,707,000	10,750,000	5,914,000	1,416,000	949,000
R&D Expenses	-8.7%	8,167,000	8,949,000	8,056,000	8,103,000	7,936,000	7,135,000	11,236,000	10,182,000	8,648,000	9,098,000	9,369,000	8,111,000	7,719,000	6,370,000	6,855,000	6,118,000	4,855,000	4,874,000	4,219,000	4,783,000	3,898,000
EBITDA Margin	100.0%	-	-0.07	-0.13	-0.18	-0.28	-0.32	-0.34	-0.38	-0.39	-0.39	-0.50	-0.47	-0.73	-1.51	-2.02	-5.60	-	-	-	-	-
Interest Expenses	-59.0%	16,000	39,000	-	-	-	-	1,000	-	1,000	2,007,000	170,000	253,000	256,000	264,000	329,000	339,000	367,000	370,000	360,000	358,000	188,000
Income Taxes	-40.5%	-427,000	-304,000	-807,000	-522,000	-520,000	-465,000	-1,111,000	-2,487,000	528,000	3,296,000	-555,000	-	-	-	1,000	-	-	1,000	-	-	-
Earnings Before Taxes	145.8%	3,501,000	-7,646,000	-10,055,000	143,000	-16,772,000	-21,908,000	-23,779,000	-17,653,000	-16,722,000	-21,852,000	-23,058,000	-11,348,000	-9,168,000	-19,783,000	-14,615,000	-22,751,000	-25,006,000	-19,060,000	-13,117,000	-9,665,000	-7,566,000
EBT Margin	100.0%	-	-0.11	-0.16	-0.23	-0.33	-0.37	-0.41	-0.44	-0.45	-0.44	-0.53	-0.49	-0.77	-1.56	-2.09	-5.79	-	-	-	-	-
Net Income	153.5%	3,928,000	-7,342,000	-9,248,000	683,500	-16,252,000	-21,443,000	-22,668,000	-15,166,500	-17,250,000	-25,148,000	-22,503,000	-11,348,000	-9,168,000	-19,783,000	-14,616,000	-22,751,000	-25,006,000	-19,061,000	-13,117,000	-9,665,000	-7,566,000
Net Income Margin	100.0%	-	-0.10	-0.16	-0.22	-0.31	-0.35	-0.41	-0.44	-0.47	-0.45	-0.53	-0.49	-0.77	-1.56	-2.09	-5.79	-	-	-	-	-
Free Cashflow	100.0%	-	-19,465,000	-1,575,000	9,018,000	2,884,000	-1,476,000	-9,458,000	-7,860,000	-3,678,000	-12,323,000	-25,706,000	-29,337,000	-19,794,000	-13,528,000	-24,021,000	-28,513,000	-	-	-	-	-

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	1.8%	661	649	666	659	632	514	526	548	561	566	445	342	348	349	217	220	126	146	159	172	42.00
Current Assets	4.4%	475	455	470	465	449	313	307	321	330	332	228	328	334	336	204	212	118	138	153	165	35.00
Cash Equivalents	1.4%	147	145	240	239	241	203	213	221	229	231	131	241	269	288	160	171	76.00	83.00	89.00	98.00	20.00
Inventory	6.9%	75.00	70.00	66.00	56.00	58.00	58.00	62.00	65.00	70.00	70.00	71.00	63.00	44.00	30.00	19.00	16.00	13.00	8.00	5.00	4.00	2.00
Net PPE	3.3%	7.00	6.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00	6.00	6.00	6.00	6.00	6.00	5.00	3.00	3.00	3.00	3.00	3.00	3.00
Goodwill	-3.6%	95.00	99.00	97.00	94.00	87.00	95.00	103	106	110	107	87.00	-	-	-	-	-	-	-	-	-	-
Liabilities	3.4%	50.00	48.00	89.00	89.00	83.00	76.00	62.00	66.00	71.00	61.00	115	55.00	54.00	51.00	45.00	37.00	34.00	32.00	28.00	29.00	18.00
Current Liabilities	10.9%	36.00	32.00	66.00	65.00	61.00	30.00	26.00	27.00	28.00	24.00	24.00	46.00	39.00	31.00	20.00	12.00	16.00	11.00	7.00	6.00	5.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	21.00	15.00	10.00	5.00	-	6.00	4.00	2.00	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	0.00	75.00	-	6.00	11.00	16.00	20.00	14.00	16.00	18.00	19.00	9.00
Shareholder's Equity	1.7%	611	601	577	570	550	438	463	482	490	504	330	287	294	298	172	183	92.00	114	131	143	-
Retained Earnings	1.0%	-386	-390	-383	-374	-374	-358	-337	-314	-299	-282	-257	-234	-223	-213	-194	-179	-156	-131	-112	-99.65	-89.98
Additional Paid-In Capital	1.2%	1,022	1,010	982	970	961	821	812	804	796	788	590	522	518	513	367	363	250	247	245	243	3.00
Shares Outstanding	0.4%	51.00	50.00	50.00	50.00	47.00	45.00	45.00	46.00	45.00	43.00	40.00	40.00	39.00	36.00	34.00	34.00	28.00	28.00	28.00	7.00	3.00

Cashflow (Last 12 Months)
(In Millions)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	164.3%	12,344	-19,209	-781	9,353	3,847	-842	-9,167	-6,776	-2,994	-11,953	-25,583	-28,314	-19,146	-12,975	-23,307	-28,136	-23,904	-18,359	-13,055	-9,296	-8,102
Share Based Compensation	2.4%	11,470	11,204	10,714	8,757	8,218	7,905	7,138	6,844	6,690	6,327	5,303	3,582	3,775	3,816	3,922	2,921	2,782	1,875	1,142	247	101
Cashflow From Investing	83.9%	-11,053	-68,623	694	-10,030	-99,401	-10,632	-291	-1,084	-684	-370	-140,864	-1,023	-648	-553	11,878	12,342	17,456	11,440	4,049	-48,115	3,516
Cashflow From Financing	113.0%	878	-6,766	1,930	161	131,883	480	1,444	202	1,523	112,573	56,215	1,055	1,296	141,495	344	110,492	111	308	44.00	135,579	6.00

AXNX Income Statement

2023-09-30

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net revenue	$ 93,100	$ 70,384	$ 256,644	$ 187,784
Cost of goods sold	23,996	19,124	64,850	53,086
Gross profit	69,104	51,260	191,794	134,698
Operating expenses
Research and development	8,167	7,936	25,172	26,307
General and administrative	11,778	9,389	34,659	29,974
Sales and marketing	47,544	39,751	134,468	112,195
Amortization of intangible assets	2,302	2,317	6,803	7,112
Acquisition-related costs	0	8,242	2,368	20,447
Acquired in-process research & development	0	0	15,447	0
Total operating expenses	69,791	67,635	218,917	196,035
Loss from operations	(687)	(16,375)	(27,123)	(61,337)
Other income (expense)
Interest and other income	4,271	1,501	12,149	1,904
Interest and other expense	(83)	(1,898)	774	(3,026)
Other income (expense), net	4,188	(397)	12,923	(1,122)
Income (loss) before income tax benefit	3,501	(16,772)	(14,200)	(62,459)
Income tax benefit	(427)	(520)	(1,538)	(2,096)
Net income (loss)	3,928	(16,252)	(12,662)	(60,363)
Foreign currency translation adjustment	(6,185)	(12,057)	636	(29,625)
Comprehensive loss	$ (2,257)	$ (28,309)	$ (12,026)	$ (89,988)
Net income (loss) per share, basic (in USD per share)	$ 0.08	$ (0.34)	$ (0.26)	$ (1.31)
Weighted-average shares used to compute basic net income (loss) per share (in shares)	49,244,981	47,208,192	48,973,252	46,185,209
Net income (loss) per share, diluted (in USD per share)	$ 0.08	$ (0.34)	$ (0.26)	$ (1.31)
Weighted-average shares used to compute diluted net income (loss) per share (in shares)	50,086,491	47,208,192	48,973,252	46,185,209

AXNX Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 147,323	$ 238,846
Short-term investments	197,393	118,365
Accounts receivable, net of allowance for credit losses of $380 and $321 at September 30, 2023 and December 31, 2022, respectively	48,944	44,817
Inventory, net	74,909	55,765
Prepaid expenses and other current assets	6,816	7,282
Total current assets	475,385	465,075
Property and equipment, net	6,556	6,798
Intangible assets, net	80,274	86,253
Other assets	3,245	6,813
Goodwill	95,287	94,414
Total assets	660,747	659,353
Current liabilities
Accounts payable	14,666	9,070
Accrued liabilities	5,962	6,520
Accrued compensation and benefits	12,994	15,495
Operating lease liabilities, current portion	1,971	1,562
Other current liabilities	0	32,600
Total current liabilities	35,593	65,247
Operating lease liabilities, net of current portion	876	7,555
Deferred tax liabilities, net	13,658	16,412
Total liabilities	50,127	89,214
Commitments and contingencies (Note 3)
Stockholders’ equity
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2023 and December 31, 2022	0	0
Common stock, par value $0.0001, 75,000,000 shares authorized at September 30, 2023 and December 31, 2022; 50,669,203 and 49,546,727 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	5	5
Additional paid-in capital	1,022,052	969,545
Accumulated deficit	(386,926)	(374,264)
Accumulated other comprehensive loss	(24,511)	(25,147)
Total stockholders’ equity	610,620	570,139
Total liabilities and stockholders’ equity	$ 660,747	$ 659,353

About Axonics Modulation Technologies Inc

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

CEO	Mr. Raymond W. Cohen
WEBSITE	www.axonics.com
EMPLOYEES	610

Axonics Modulation Technologies Inc Frequently Asked Questions

What is the ticker symbol for Axonics Modulation Technologies Inc? What does AXNX stand for in stocks?

AXNX is the stock ticker symbol of Axonics Modulation Technologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Axonics Modulation Technologies Inc (AXNX)?

As of Thu Dec 07 2023, market cap of Axonics Modulation Technologies Inc is 2.93 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXNX stock?

You can check AXNX's fair value in chart. The fair value of Axonics Modulation Technologies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Axonics Modulation Technologies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Axonics Modulation Technologies Inc a good stock to buy?

The fair value guage provides a quick view whether AXNX is over valued or under valued. Whether Axonics Modulation Technologies Inc is cheap or expensive depends on the assumptions which impact Axonics Modulation Technologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXNX.

What is Axonics Modulation Technologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 07 2023, AXNX's PE ratio (Price to Earnings) is -244.92 and Price to Sales (PS) ratio is 8.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXNX PE ratio will change depending on the future growth rate expectations of investors.

Market Summary

AXNX Alerts

AXNX Stock Price

AXNX RSI Chart

AXNX Alerts

AXNX Valuation

AXNX Price/Sales (Trailing)

AXNX Profitability

AXNX Fundamentals

AXNX Revenue

AXNX Earnings

Price Action

How does AXNX drawdown profile look like?

AXNX Financial Health

AXNX Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for AXNX

Which funds bought or sold AXNX recently?

Latest Funds Activity

Schedule 13G FIlings of Axonics Modulation Technologies Inc

Recent SEC filings of Axonics Modulation Technologies Inc

Peers (Alternatives to Axonics Modulation Technologies Inc)

Axonics Modulation Technologies Inc News

Financials for Axonics Modulation Technologies Inc

Income Statement (Last 12 Months)

Balance Sheet.css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Cashflow (Last 12 Months)(In Millions)

AXNX Income Statement

AXNX Balance Sheet

About Axonics Modulation Technologies Inc

Axonics Modulation Technologies Inc Frequently Asked Questions

What is the ticker symbol for Axonics Modulation Technologies Inc? What does AXNX stand for in stocks?

What is the market capital of Axonics Modulation Technologies Inc (AXNX)?

What is the fair value of AXNX stock?

Is Axonics Modulation Technologies Inc a good stock to buy?

What is Axonics Modulation Technologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)